{"name": "ESBATech",
 "permalink": "esbatech",
 "crunchbase_url": "http://www.crunchbase.com/company/esbatech",
 "homepage_url": "http://www.esbatech.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1998,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@esbatech.com",
 "phone_number": "41-44-733-4900",
 "description": "Antibody framework therapeutics",
 "created_at": "Wed Jun 24 08:32:13 UTC 2009",
 "updated_at": "Tue Apr 20 03:51:53 UTC 2010",
 "overview": "\u003Cp\u003EFounded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain antibody frameworks to generate product candidates against targets of clinical relevance. ESBATech is focused on delivering high concentrations of its therapeutic antibody fragments to the targeted sites, in combination with extremely low systemic load, in order to achieve low risk of systemic drug reactions using topical and local delivery.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       54],
      "assets/images/resized/0005/0466/50466v1-max-150x150.png"],
     [[239,
       87],
      "assets/images/resized/0005/0466/50466v1-max-250x250.png"],
     [[239,
       87],
      "assets/images/resized/0005/0466/50466v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chief Executive Officer",
    "person":
     {"first_name": "Dominik",
      "last_name": "Escher",
      "permalink": "dominik-escher",
      "image":
       {"available_sizes":
         [[[100,
            150],
           "assets/images/resized/0005/0468/50468v1-max-150x150.jpg"],
          [[120,
            180],
           "assets/images/resized/0005/0468/50468v1-max-250x250.jpg"],
          [[120,
            180],
           "assets/images/resized/0005/0468/50468v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Chief Financial Officer",
    "person":
     {"first_name": "Martin",
      "last_name": "Gertsch",
      "permalink": "martin-gertsch",
      "image":
       {"available_sizes":
         [[[100,
            150],
           "assets/images/resized/0005/0469/50469v1-max-150x150.jpg"],
          [[120,
            180],
           "assets/images/resized/0005/0469/50469v1-max-250x250.jpg"],
          [[120,
            180],
           "assets/images/resized/0005/0469/50469v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$63M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/story/esbatech-rounds-additional-22m-series-b/2008-08-07",
    "source_description": "ESBATech rounds up $22M in second round",
    "raised_amount": 22000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 8,
    "funded_day": 7,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "SV Life Sciences",
         "permalink": "sv-life-sciences",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/5361/45361v2-max-150x150.png"],
             [[250,
               84],
              "assets/images/resized/0004/5361/45361v2-max-250x250.png"],
             [[332,
               112],
              "assets/images/resized/0004/5361/45361v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Clarus Ventures",
         "permalink": "clarus-ventures",
         "image":
          {"available_sizes":
            [[[150,
               82],
              "assets/images/resized/0005/0042/50042v2-max-150x150.png"],
             [[250,
               137],
              "assets/images/resized/0005/0042/50042v2-max-250x250.png"],
             [[308,
               169],
              "assets/images/resized/0005/0042/50042v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HBM BioVentures",
         "permalink": "hbm-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0482/50482v1-max-150x150.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-250x250.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HBM BioCapital",
         "permalink": "hbm-biocapital",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0565/50565v1-max-150x150.png"],
             [[156,
               27],
              "assets/images/resized/0005/0565/50565v1-max-250x250.png"],
             [[156,
               27],
              "assets/images/resized/0005/0565/50565v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Bioventures",
         "permalink": "novartis-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0006/1683/61683v1-max-150x150.png"],
             [[250,
               98],
              "assets/images/resized/0006/1683/61683v1-max-250x250.png"],
             [[380,
               150],
              "assets/images/resized/0006/1683/61683v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BioMedinvest",
         "permalink": "biomedinvest",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0005/0483/50483v3-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0005/0483/50483v3-max-250x250.png"],
             [[266,
               44],
              "assets/images/resized/0005/0483/50483v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "VI Partners",
         "permalink": "vi-partners",
         "image":
          {"available_sizes":
            [[[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-150x150.jpg"],
             [[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-250x250.jpg"],
             [[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://esbatech.com/pr/press_releases/esbatech_press_02082006.pdf",
    "source_description": "ESBATech Closes USD 41M Series B Venture Financing",
    "raised_amount": 41000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2006,
    "funded_month": 8,
    "funded_day": 2,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "SV Life Sciences",
         "permalink": "sv-life-sciences",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/5361/45361v2-max-150x150.png"],
             [[250,
               84],
              "assets/images/resized/0004/5361/45361v2-max-250x250.png"],
             [[332,
               112],
              "assets/images/resized/0004/5361/45361v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Clarus Ventures",
         "permalink": "clarus-ventures",
         "image":
          {"available_sizes":
            [[[150,
               82],
              "assets/images/resized/0005/0042/50042v2-max-150x150.png"],
             [[250,
               137],
              "assets/images/resized/0005/0042/50042v2-max-250x250.png"],
             [[308,
               169],
              "assets/images/resized/0005/0042/50042v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HBM BioVentures",
         "permalink": "hbm-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0482/50482v1-max-150x150.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-250x250.png"],
             [[156,
               27],
              "assets/images/resized/0005/0482/50482v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HBM BioCapital",
         "permalink": "hbm-biocapital",
         "image":
          {"available_sizes":
            [[[150,
               25],
              "assets/images/resized/0005/0565/50565v1-max-150x150.png"],
             [[156,
               27],
              "assets/images/resized/0005/0565/50565v1-max-250x250.png"],
             [[156,
               27],
              "assets/images/resized/0005/0565/50565v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Venture Fund",
         "permalink": "novartis-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               70],
              "assets/images/resized/0005/9083/59083v2-max-150x150.png"],
             [[250,
               117],
              "assets/images/resized/0005/9083/59083v2-max-250x250.png"],
             [[318,
               150],
              "assets/images/resized/0005/9083/59083v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BioMedinvest",
         "permalink": "biomedinvest",
         "image":
          {"available_sizes":
            [[[150,
               24],
              "assets/images/resized/0005/0483/50483v3-max-150x150.png"],
             [[250,
               41],
              "assets/images/resized/0005/0483/50483v3-max-250x250.png"],
             [[266,
               44],
              "assets/images/resized/0005/0483/50483v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "VI Partners",
         "permalink": "vi-partners",
         "image":
          {"available_sizes":
            [[[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-150x150.jpg"],
             [[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-250x250.jpg"],
             [[117,
               134],
              "assets/images/resized/0005/0484/50484v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": null,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://invest.alconinc.com/phoenix.zhtml?c=130946\u0026p=irol-pressReleasesArticle\u0026ID=1331107\u0026highlight=",
   "source_description": "Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG",
   "acquired_year": 2009,
   "acquired_month": 9,
   "acquired_day": 13,
   "acquiring_company":
    {"name": "Alcon",
     "permalink": "alcon",
     "image":
      {"available_sizes":
        [[[150,
           47],
          "assets/images/resized/0006/0451/60451v1-max-150x150.jpg"],
         [[183,
           58],
          "assets/images/resized/0006/0451/60451v1-max-250x250.jpg"],
         [[183,
           58],
          "assets/images/resized/0006/0451/60451v1-max-450x450.jpg"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Wagistr. 21",
    "address2": "CH-8952 Zurich-Schlieren",
    "zip_code": "",
    "city": "",
    "state_code": null,
    "country_code": "CHE",
    "latitude": 47.3993302,
    "longitude": 8.4582269}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        110],
       "assets/images/resized/0005/0467/50467v1-max-150x150.jpg"],
      [[250,
        184],
       "assets/images/resized/0005/0467/50467v1-max-250x250.jpg"],
      [[450,
        332],
       "assets/images/resized/0005/0467/50467v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}